Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study바리시티닙은 SARS-CoV-2 폐렴에 대한 코르티코스테로이드 치료 환자의 호흡 기능을 개선합니다: 관찰 코호트 연구Observational Study Published on 2021-01-052022-09-11 Journal: Rheumatology (Oxford, England) [Category] 임상, 진단, 치료제, [키워드] adjusted arterial oxygen partial pressure Baricitinib block viral entry Combination Corticosteroid Corticosteroids COVID-19 cytokine Cytokine storm discharge end point enrolled European FiO2 greater HCQ High-dose Hospitalization IMPROVE inhibitor Jak Janus kinase Lopinavir Lopinavir/ritonavir moderate moderate to severe network Observational cohort study observational study oxygen oxygen partial pressure oxygen saturation PaO2 partial pressure Patient patients treated patients with moderate patients with SARS-CoV-2 pharmacoepidemiology pharmacovigilance pneumocyte Pneumocytes Pneumonia Prevent primary end point proportion Pulmonary function pulse oximetry reduction required requiring supplemental oxygen Respiratory function risk Ritonavir SARS-CoV-2 SARS-CoV-2 pneumonia secondary severe SARS-CoV-2 SpO2 SpO2/FiO2 Statistics supplemental oxygen Viral viral entry Weighting [DOI] 10.1093/rheumatology/keaa587 PMC 바로가기 [Article Type] Observational Study
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 EpidemicObservational Study Published on 2021-01-012022-10-05 Journal: Clinical and translational science [Category] SARS, 임상, [키워드] Adverse drug reaction approved bradycardia cardiac toxicity Cardiomyopathy Cardiotoxicity Characteristics comparative observational study concerning coronavirus disease COVID-19 database disorder Estimated evidence of French HCQ incidence increasingly indication insight off-label Patient patients treated performed pharmacovigilance retrospective rheumatoid arthritis significantly significantly higher statistically use of hydroxychloroquine ventricular [DOI] 10.1111/cts.12883 PMC 바로가기 [Article Type] Observational Study
Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactionsObservational Study Published on 2020-12-232022-10-04 Journal: Internal and Emergency Medicine [Category] MERS, SARS, 임상, [키워드] addition ADR ADRS Adverse drug reaction Adverse drug reactions age Caucasian patient Characteristics Clinical characteristics collected Comorbidities COVID-19 COVID-19 patient disorders drug–drug interaction Drug–drug interactions drugs effective evaluated Evidence Florence hospitalised hospitalised patient Hospitalised patients identify Interaction interactions internal medicine Italy less majority males medications outcome patients pharmacokinetic pharmacological pharmacovigilance preferred term Psychiatric QT interval QT prolongation reported resolved risk SARS-CoV-2 study period supplementary material treatments for COVID-19 unit university [DOI] 10.1007/s11739-020-02586-8 PMC 바로가기 [Article Type] Observational Study
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand태국에서 청소년과 성인을 위한 단가(재조합 비세포 백신) 및 파상풍, 저용량 디프테리아 조합(TdaP, Boostagen®) 백신으로 면역화하기 위해 허가된 새로운 재조합 비세포 백신에 대한 향상된 면허 후 안전 감시Article Published on 2020-12-032024-08-18 Journal: Vaccine [Category] 백일해, 파상풍, [키워드] booster pertussis pharmacovigilance post-licensure Pregnancy recombinant Safety [DOI] 10.1016/j.vaccine.2020.10.070
Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary DataPharmacology Published on 2020-12-032022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 95% CI Acute kidney injury Adverse adverse (side) effects Adverse drug reaction ALS analyzed Anemia caution cerebrospinal fluid chloroquine/hydroxychloroquine Corona corona virus disease-19 (COVID-19) COVID-19 patient COVID-19 patients Dexamethasone distribution drug eosinophilia Hepatitis hepatotoxic hospital hospitalized patient hyponatremia incidence incidence rate induce Laboratory leukocyte Lopinavir-ritonavir medication neutropenia non-COVID-19 patient Non-COVID-19 patients pandemic patients patients with COVID-19 pharmacovigilance pharmacovigilance process Program reaction reflected serious adverse drug reaction signal Spain Suspected Tertiary the SARS-CoV-2 Thromboembolic events Tocilizumab [DOI] 10.3389/fphar.2020.602841 PMC 바로가기 [Article Type] Pharmacology
Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infectionSARS-CoV-2 감염 치료에 특별히 사용되는 약물의 부작용Review Published on 2020-11-272022-09-11 Journal: Medicina clínica [Category] 치료제, [키워드] Adverse Adverse drug reaction Adverse drug reactions adverse effect Adverse reaction Adverse reactions Alergia a medicamento allergy approved COVID-19 COVID-19 treatment described disease drug Drug allergy drug reaction Efficacy and safety healthcare worker Healthcare workers hospital immunological Infection Inflammatory response initial Numerous pandemic pharmacovigilance Program Reacción adversa a medicamento Registered SARS-CoV-2 SARS-COV-2 infection the SARS-CoV-2 thought Tratamiento COVID-19. Treatment Viral viral infection [DOI] 10.1016/j.medcli.2020.06.019 PMC 바로가기 [Article Type] Review
Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting아르테미시닌 기반 복합 요법의 의심되거나 확인된 치료 효과 없음에 대한 약물 감시: 범위, 관련 요인, 도전 과제 및 보고에 대한 해결책Research Published on 2020-11-032024-08-11 Journal: Malaria Journal [Category] 말라리아, [키워드] Artemisinin-based combination therapy healthcare professionals pharmacovigilance Reporting of artemisinin-based combination therapy failure Therapeutic effectiveness therapeutic efficacy Therapeutic ineffectiveness Therapeutic inefficacy [DOI] 10.1186/s12936-020-03463-7 PMC 바로가기 [Article Type] Research
Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion코로나바이러스 질병 2019(COVID-19) 확산 및 약물감시 영향: 전문가 의견Editorial Published on 2020-11-012022-09-11 Journal: Therapeutic innovation & regulatory science [Category] SARS, 치료제, [키워드] approved China Chloroquine clinical trial Community condition consequence coronavirus disease Coronavirus disease 2019 Coronaviruses COVID-19 expert Healthcare systems Hydroxychloroquine in viral in vitro study individual Infection Infection prevention management measure Medicine opinion other conditions Patient pharmacovigilance Pharmacy physician pressure Prevention and control resulting supportive care therapy Toxicity Treatment treatments for COVID-19 viable treatment Viral Viral resistance [DOI] 10.1007/s43441-020-00158-8 PMC 바로가기 [Article Type] Editorial
Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspectiveResearch article Published on 2020-11-012022-10-05 Journal: Food and chemical toxicology : an international jo [Category] SARS, 신약개발, 치료제, [키워드] adverse event Analysis antiviral therapeutics approach approaches association clinical evidence Clinical practice clinical trials CMap Comprehensive coronavirus disease Course COVID-19 COVID-19 drug drug drugs FDA food gene-set enrichment analysis global public health GSEA human tissue identify labeling lung Network proximity occurred OpenVigil patients with COVID-19 performed Perspective pharmacovigilance provide renal Safe safety profile SARS-CoV-2 Side effect therapeutic agent tissues Toxicity Treatment [DOI] 10.1016/j.fct.2020.111767 [Article Type] Research article
A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?Case Report Published on 2020-10-062022-11-01 Journal: Clinical and Molecular Allergy : CMA [Category] COVID-19, [키워드] Activation Adverse Adverse Drug Reaction (ADR) ALDEN Algorithm Algorithm Antibiotics Atypical Blister calculated cardiometabolic Case report caused clinical evidence COVID 19 COVID-19 COVID-19 positive patient Cutaneous detect Dexamethasone drug epidermal extension highest Hydroxychloroquine immune system knowledge lesion less low-molecular-weight-heparin Manifestations mucous membrane Necrolysis off-label Other outcome pandemic Paracetamol Patient patient with COVID-19 pharmacovigilance potassium canrenoate Rash reaction regimen respiratory retrieved SARS-CoV- 2 SCORTEN Score Severe Cutaneous Adverse Reactions (SCAR) Stevens–Johnson Syndrome (SJS) syndrome the patient total body Toxic Epidermal Necrolysis (TEN) toxicities treated virus widespread [DOI] 10.1186/s12948-020-00133-6 PMC 바로가기 [Article Type] Case Report